Merck and Isomorphic Labs Form AI Oncology Drug Discovery Partnership

industry_news

Merck and Isomorphic Labs Form AI Oncology Drug Discovery Partnership

Updated on Nov 20, 2026, 02:31 AM IST
Written & Edited by Harikesh VA

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Isomorphic Labs, an AI-first drug design and development company, announced a strategic research collaboration that pairs Isomorphic Labs' artificial intelligence approach to drug discovery with Merck's proprietary data resources and discovery experience.

 

The partnership, announced from Rahway, New Jersey, focuses on discovering therapeutic small molecule candidates against an oncology target described as being of strategic importance.

 

Deal Overview

Under the agreement, Isomorphic Labs will perform in silico predictions and deliver molecular designs using its proprietary drug design engine, known as IsoDDE.

 

For the purposes of the collaboration, Merck will supply select high-quality proprietary data sets to be incorporated into the engine. Merck will retain responsibility for preclinical and clinical development, as well as manufacturing and commercialization of any products derived from the collaboration.

 

Financial Terms

Isomorphic Labs will receive an upfront payment from Merck and will be eligible for additional payments tied to the achievement of specified research, development, regulatory and commercial milestones.

 

The agreement also provides for tiered royalties on net sales. In addition, Isomorphic Labs holds an option to co-fund development activities in return for elevated royalties. Specific dollar amounts for the upfront payment and milestone opportunities were not disclosed in the announcement.

Trusted by Leading EPCs & Manufacturers

Find the Latest Pharmaceutical Plant Projects Around the World

Gain exclusive access to our industry-leading database of pharmaceutical plant opportunities with detailed project timelines and stakeholder information

Request Free Trial → Learn More →

No credit card Up-to-date coverage

 

Leadership Perspectives

George Addona, senior vice president and head of discovery, preclinical development, and translational medicine at Merck Research Laboratories, emphasized the operational integration required for AI-driven molecular invention.

 

"The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions," Addona said. "By combining Merck's substantial internal data capabilities and discovery expertise with Isomorphic Labs' powerful modeling and compute capabilities, we aim to identify new ways to design and create better candidates faster."

On the Isomorphic Labs side, chief research officer Sarah Skerratt framed the deal as an opportunity to deploy the company's technology against a difficult drug discovery problem.

 

"Through this collaboration with Merck, we will apply our world-leading drug design engine to unlock significant discovery progress," Skerratt said. "By leveraging the generative and predictive power of the IsoDDE to address this challenging program, this collaboration highlights our companies' shared commitment to innovation for the benefit of patient populations with unmet needs."

The companies described the collaboration as demonstrating the transformative power of combining advanced AI, unique data sets, and established biopharmaceutical leadership to accelerate the advancement of therapeutic candidates, navigating complex biology with what they characterized as unprecedented speed and precision.

About Isomorphic Labs

Isomorphic Labs was founded in 2021 with the aim of transforming drug discovery through artificial intelligence. The company is led by CEO Sir Demis Hassabis and President Max Jaderberg.

 

The company has built a modality-agnostic drug design engine, IsoDDE, comprised of foundational AI models, which the company says provides the predictive fidelity required to navigate novel biological systems with unprecedented accuracy. The company also states it continually innovates on model architecture and develops cutting-edge capabilities to advance drug design.

Isomorphic Labs is headquartered in London, with office locations in Cambridge, Massachusetts, and Lausanne, Switzerland. The company is advancing a drug design portfolio through both partnered programs and wholly owned internal programs.

About Merck

Merck, which traces more than 130 years of developing medicines and vaccines, describes its purpose as using the power of leading-edge science to save and improve lives around the world.

 

The company aspires to be the premier research-intensive biopharmaceutical company in the world and positions itself at the forefront of research to deliver innovative health solutions advancing the prevention and treatment of diseases in people and animals.

From Initial Concept to Final Implementation: Every Chemical Project, One Platform

What distinguishes successful teams from those that lag behind? Proactive insights. Across the global chemical market, the most effective developers, contractors, and suppliers are not merely responding to project updates; they are taking action months in advance, well before competitors are even aware of emerging opportunities.

 

The Global Project Tracking (GPT) platform by Blackridge Research provides a competitive advantage in the chemical sector: a single, continuously updated database of capital projects spanning various chemical industries worldwide, meticulously curated by analysts to highlight opportunities rather than distractions.

 

Whether you're focusing on a chemical plant expansion, a pipeline project, or a specialty chemical facility, your next contract is already in the pipeline; the question is whether you'll discover it first.

 

  • Upcoming Projects

  • Tender Notices

  • Contract Awards

  • Projects Under Construction

  • Completed Projects

 

Book a Free Demo today and discover how the Global Project Tracking (GPT) platform by Blackridge Research can turn global chemical project data into your most reliable source of new business.

Tags

Leave a Comment

We love hearing from our readers and value your feedback. If you have any questions or comments about our content, feel free to leave a comment below.

We read every comment and do our best to respond to them all.

Protected by Cloudflare Turnstile